The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data

Scandinavian Journal of Rheumatology

Volumn 37, Issue 1, 2008, Pages 62-71

  Kobelt, G ^a,b   Sobocki, P ^c   Mulero, J ^d   Gratacos, J ^e   Collantes Estevez, E ^f   Braun, J ^g  

^a LUND UNIVERSITY   (Sweden)

^b European Health Economics ^*  (France)

^c European Health Economics   (Sweden)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL DE SABADELL   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PLACEBO;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL ASPECT; SPAIN;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; COSTS AND COST ANALYSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; PLACEBOS; SPAIN; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 38349048659     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740701607224     Document Type: Article

References (33)

1. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
2. Boonen A, Severens JL. Ankylosing spondylitis: what is the cost to society, and can it be reduced? Best Pract Res Clin Rheumatol 2002;16:691-705.
3. Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-van Molken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
4. Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab. Rheumatol 2004;43:1158-66.
5. Kobelt G, Andlin-Sobocki P, Rousseau C, Maksymowych W. Cost and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 2006;33:289-95.
6. Kobelt G, Sobocki P, Collantes-Estevez E, Gratacos-Masmita J, Pocovi A, Mlero-Mendoza J. The cost of ankylosing spondylitis in Spain. An observational study in 600 patients. THU0550. Ann Rheum Dis 2006;65(Suppl II):282.
7. Kobelt G, Sobocki P, Collantes-Estevez E, Gratacos-Masmita J, Pocovi A, Mulero J. The burden of ankylosing spondylitis in Spain. Value in Health, 2007. DOI: 10.1111/j.1524-4733.2007.00252.
8. Calin A, Barrett S, Whitelock H, Kennedy LG, O'Hea L, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
9. Taylor A, Balakrishnan C, Calin A. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis Rheum 1998;41:1119-25.
10. Szende A, Williams A. EuroQoL scores in Europe. Budapest, The EuroQol Group, 2004.
11. Braun J, Baraliakos X, Godolias G, Bohm H. Therapy of ankylosing spondylitis - a review. Part I: Conventional medical treatment and surgical therapy. Scand J Rheumatol 2005;34:97-108.
12. Braun J, Baraliakos X, Brandt J, Sieper J. Therapy of ankylosing spondylitis. Part II: Biological therapies in spondylarthropathies. Scand J Rheumatol 2005;34:178-90.
13. Kobelt G. Health economic issues in rheumatoid arthritis. Scand J Rheumatol 2006;35:415-25.
14. Kobelt G, Andlin-Sobocki P, Maksymowych W. The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Canada. J Rheumatol 2006;33:732-40.
15. Kobelt G, Sobocki P, Sieper J, Braun J. A comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the UK based on two different clinical trials. Int J Technol Assess Health Care 2007;23:368-75.
16. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
17. J B, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open observational extension study of a three-month randomized placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.
18. Braun J, Brandt H, Listing J, Listing J, Zink A, Burmester G, et al. Two-year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.
19. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Altern R, et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005;44:670-6.
20. Myckatyn S, Mallon C, Russell A, Maksymowych W. 3 Year follow-up of a prospective observational inception cohort of ankylosing spondylitis patients on low-dose (3 mg/kg) infliximab. Ann Rheum Dis 2004;63(Suppl 1):408.
21. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized placebo/controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
22. Collantes-Estevez E, Munoz-Villanueva M, Zarco P, Torre-Alonso JC, Gratacos J, Gonzalez C, et al. Infliximab in refractory spondylarthropathies: a multicenter 38-week open study. Ann Rheum Dis 2003;62:1239-40.
23. Collantes-Estevez E, Munoz-Villanueva M, Zarco P, Torre-Alonso JC, Gratacos J, Gonzalez C, et al. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondylarthropathies. An open extension of a multicentre study. Rheumatol 2005;44:1555-8.
24. Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, et al. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology (Oxford) 2005;44:939-47.
25. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
26. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. York: Centre for Health Economics, University of York, 1995. Discussion paper 138.
27. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52:174-6.
28. Jois RN, Leeder L, Gibb A, Gaffney K, Macgregor A, Somerville M, et al. Low-dose infliximab treatment for ankylosing spondylitis - clinically- and cost-effective. Rheumatology (Oxford) 2006;45:1566-9.
29. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600-6.
30. Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006;8:R72.
31. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005;64:1462-6.
32. Boonen A, van der Heijde D, Severens JL, Boendemaker A, Landdewe R, Braun J, et al. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 2006;65:201-8.
33. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89.